|
1
|
Murali R, Soslow RA and Weigelt B:
Classification of endometrial carcinoma: More than two types.
Lancet Oncol. 15:e268–e278. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cancer Genome Atlas Research Network, ;
Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H,
Robertson AG, Pashtan I, Shen R, et al: Integrated genomic
characterization of endometrial carcinoma. Nature. 497:67–73. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Marchiò C, De Filippo MR, Ng CK,
Piscuoglio S, Soslow RA, Reis-Filh JS and Weigelt B: PIKing the
type and pattern of PI3K pathway mutations in endometrioid
endometrial carcinomas. Gynecol Oncol. 137:321–328. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
McConechy MK, Ding J, Cheang MCU, Wiegand
K, Senz J, Tone A, Yang W, Prentice L, Tse K, Zeng T, et al: Use of
mutation profiles to refine the classification of endometrial
carcinomas. J Pathol. 228:20–30. 2012.PubMed/NCBI
|
|
5
|
Salvesen HB, Carter SL, Mannelqvist M,
Dutt A, Getz G, Stefansson IM, Raeder MB, Sosh ML, Engelsen IB,
Trovik J, et al: Integrated genomic profiling of endometrial
carcinoma associates aggressive tumors with indicators of PI3
kinase activation. Proc Natl Acad Sci USA. 106:4834–4839. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oda K, Stokoe D, Taketani Y and McCormick
F: High frequency of coexistent mutations of PIK3CA, PTEN
genes in endometrial carcinoma. Cancer Res. 65:10669–10673. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Catasus L, D'Angelo E, Pons C, Espinosa I
and Prat J: Expression profiling of 22 genes involved in the
PI3K-AKT pathway identifies two subgroups of high-grade endometrial
carcinomas with different molecular alterations. Mod Path.
23:694–702. 2010. View Article : Google Scholar
|
|
8
|
Hayes MP, Wang H, Espinal-Witter R,
Douglas W, Solomon GJ, Baker SJ and Ellenson HL: PIK3CA,
PTEN mutations in uterine endometrioid carcinoma and complex
atypical hyperplasia. Clin Cancer Res. 12:5932–5935. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
van der Zee M, Jia Y, Wang Y,
Heijmans-Antonissen C, Ewing PC, Franken P, DeMayo FJ, Lydon JP,
Burger CW, Fodde R, et al: Alterations in Wnt-β-catenin and
Pten signalling play distinct roles in endometrial cancer
initiation and progression. J Pathol. 230:48–58. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sal V, Demirkiran F, Erenel H, Tokgozoglu
N, Kahramanoglu I, Bese T, Turan H, Sofiyeva N, Calay Z, Arvas M
and Guralp O: Expression of PTEN and β-catenin and their
relationship with clinicopathological and prognostic factors in
endometrioid type endometrial cancer. Int J Gynecol Cancer.
26:512–520. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
McConechy MK, Ding J, Senz J, Yang W,
Melnyk N, Tone AA, Prentice LM, Wiegand KC, McAlpine JN, Shah SP,
et al: Ovarian and endometrial endometrioid carcinomas have
distinct CTNNB1 and PTEN mutation profiles. Mod Pathol. 27:128–134.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Machin P, Catasus L, Pons C, Muñoz J,
Matias-Guiu X and Prat J: CTNNB1 mutations and beta-catenin
expression in endometrial carcinomas. Hum Pathol. 33:206–212. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tejerizo-García A, Jiménez-López JS,
Muñoz-González JL, Bartolomé-Sotillos S, Marqueta-Marqués L,
López-González G and Gómez JF: Overall survival and disease-free
survival in endometrial cancer: Prognostic factors in 276 patients.
Onco Targets Ther. 6:1305–1313. 2013.
|
|
14
|
Mang C, Birkenmaier A, Cathomas G and
Humburg J: Endometrioid endometrial adenocarcinoma: An increase of
G3 cancers? Arch Gynecol Obstet. 295:1435–1440. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Voss MA, Ganesan R, Ludeman L, McCarthy K,
Gornall R, Schaller G, Wei W and Sundar S: Should grade 3
endometrioid endometrial carcinoma be considered a type 2 cancer-a
clinical and pathological evaluation. Gynecol Oncol. 124:15–20.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yasuda M: Immunohistochemical
characterization of endometrial carcinomas: Endometrioid, serous
and clear cell adenocarcinomas in association with genetic
analysis. J Obstet Gyneacol Res. 40:2137–2176. 2014.
|
|
17
|
Rudd ML, Price JC, Fogoros S, Godwin AK,
Sgroi DC, Merino MJ and Bell DW: A unique spectrum of somatic
PIK3CA (p110Aα) mutations within primary endometrial
carcinomas. Clin Cancer Res. 17:1331–1340. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mackay HJ, Eisenhauer EA, Kamel-Reid S,
Tsao M, Clarke B, Karakasis K, Werner HM, Trovik J, Akslen LA,
Salvesen HB, et al: Molecular determinants of outcome with
mammalian target of rapamycin inhibition in endometrial cancer.
Cancer. 15:603–610. 2014. View Article : Google Scholar
|
|
19
|
Mori N, Kyo S, Sakaguchi J, Mizumoto Y,
Ohno S, Maida Y, Hashimoto M, Takakura M and Inoue M: Concomitant
activation of AKT with extracellular-regulated kinase 1/2 occurs
independently of PTEN or PIK3CA mutations in
endometrial cancer and may be associated with favorable prognosis.
Cancer Sci. 98:1881–1888. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shoji K, Oda K, Kashiyama T, Ikeda Y,
Nakagawa S, Sone K, Miyamoto Y, Hiraike H, Tanikawa M, Miyasaka A,
et al: Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor,
NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial
carcinomas. PLoS One. 7:e374312012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Millis SZ, Ikeda S, Reddy S, Gatalica Z
and Kurzrock R: Landscape of phosphatidylinositol-3-kinase pathway
alterations across 19784 diverse solid tumors. JAMA Oncol.
2:1565–1573. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Catasus L, Gallardo A, Cuatrecasas M and
Prat J: Concomitant PI3K-AKT and p53 alterations in endometrial
carcinomas are associated with poor prognosis. Mod Pathol.
22:522–529. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Konopka B, Janiec-Jankowska A, Kwiatkowska
E, Najmoła U, Bidziński M, Olszewski W and Goluda C: PIK3CA
mutations and amplification in endometrioid endometrial carcinomas:
Relation to other genetic defects and clinicopathologic status of
the tumors. Hum Pathol. 42:1710–1719. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
German S, Aslam HM, Saleem S, Raees A,
Anum T, Alvi AA and Haseeb A: Carcinogenesis of PIK3CA. Hered
Cancer Clin Pract. 11:52013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
English DP, Bellone S, Cocco E, Bortolomai
I, Pecorelli S, Lopez S, Silasi DA, Schwartz PE, Rutherford T and
Santin AD: Oncogenic PIK3CA gene mutations and HER2/neu gene
amplifications determine the sensitivity of uterine serous
carcinoma cell lines to GDC-0980, a selective inhibitor of Class I
PI3 kinase and mTOR kinase (TORC1/2). Am J Obstet Gynecol.
209:465.e1–e9. 2013. View Article : Google Scholar
|
|
26
|
Dong Y, Yang X, Wong O, Zhang X, Liang Y,
Zhang Y, Wong W, Nong L, Liao Q and Li T: PIK3CA mutations
in endometrial carcinomas in Chinese women: Phosphatidylinositol
3′-kinase pathway alterations might t be associated with favorable
prognosis. Hum Pathol. 43:1197–1205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Herrero-Gonzalez S and Di Cristofano A:
New routes to old places: PIK3R1, PIK3R2 join PIK3CA,
PTEN as endometrial cancer genes. Cancer Discov. 1:106–107.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lin DI: Improved survival associated with
somatic PIK3CA mutations in copy-number low endometrioid
endometrial adenocarcinoma. Oncol Lett. 10:2743–2748. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wik E, Ræder MB, Krakstad C, Trovik J,
Birkeland E, Hoivik EA, Mjos S, Werner HM, Mannelqvist M,
Stefansson IM, et al: Lack of estrogen receptor-α is associated
with epithelial-mesenchymal transition and PI3K alterations in
endometrial carcinoma. Clin Cancer Res. 19:1094–1105. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Smith IN and Briggs JM: Structural
mutation analysis of PTEN and its genotype-phenotype correlations
in endometriosis and cancer. Proteins. 84:1625–1643. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Akiyama-Abe A, Minaguchi T, Nakamura Y,
Michikami H, Shikama A, Nakao S, Sakurai M, Ochi H, Onuki M,
Matsumoto K, et al: Loss of PTEN expression is an independent
predictor of favourable survival in endometrial carcinomas. Br J
Cancer. 109:1703–1710. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Djordjevic B, Hennessy BT, Li J, Barkoh
BA, Luthra R, Mills GB and Broaddus RR: Clinical assessment of PTEN
loss in endometrial carcinoma: Immunohistochemistry outperforms
gene sequencing. Mod Pathol. 25:699–708. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Catasus L, Gallardo A, Cuatrecasas M and
Prat J: PIK3CA mutations in the kinase domain (exon 20) of
uterine endometrial adenocarcinomas are associated with adverse
prognostic parameters. Mod Pathol. 21:131–139. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li W, Wang Y, Fang X, Zhou M, Li Y, Dong Y
and Wang R: Differential expression and clinical significance of
DNA methyltransferase 3B (DNMT3B), phosphatase and tensin homolog
(PTEN) and human MutL homologs 1 (hMLH1) in endometrial carcinomas.
Med Sci Monit. 23:938–947. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bradford LS, Rauh-Hain A, Clark RM,
Groeneweg JW, Zhang L, Borger D, Zukerberg LR, Growdon WB, Foster R
and Rueda BR: Assessing the efficacy of targeting the
phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in
endometrial cancer. Gynecol Oncol. 133:346–352. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Morice P, Leary A, Creutzberg C,
Abu-Rustum N and Darai E: Endometrial cancer. Lancet.
387:1094–1108. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Matias-Guiu X and Prat J: Molecular
pathology of endometrial carcinoma. Histopathology. 62:111–123.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
McIntyre JB, Nelson GS, Ghatage P, Morris
D, Duggan MA, Lee CH, Doll CM and Köbel M: PIK3CA missense mutation
is associated with unfavorable outcome in grade 3 endometrioid
carcinoma but not in serous endometrial carcinoma. Gynecolc Oncol.
132:188–193. 2014. View Article : Google Scholar
|
|
39
|
Miyake T, Yoshino K, Enomoto T, Takata T,
Ugaki H, Kim A, Fujiwara K, Miyatake T, Fujita M and Kimura T:
PIK3CA gene mutations and amplifications in uterine cancers,
identified by methods that avoid confounding by PIK3CA pseudogene
sequences. Cancer Lett. 261:120–126. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Garcia-Dios DA, Lambrechts D, Coenegrachts
L, Vandenput I, Capoen A, Webb PM, Ferguson K, ANECS, Akslen LA,
Claes B, et al: High-throughput interrogation of PIK3CA, PTEN,
KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
Gynecol Oncol. 128:327–334. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tsikouras P, Bouchlariotou S, Vrachnis N,
Dafopoulos A, Galazios G, Csorba R and von Tempelhoff GF:
Endometrial cancer: Molecular and therapeutic aspects. Eu J Obstet
Gynecol Reprod Biol. 169:1–9. 2013. View Article : Google Scholar
|
|
42
|
Janku F, Wheler JJ, Westin SN, Moulder SL,
Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna
I, et al: PI3K/AKT/mTOR inhibitors in patients with breast and
gynecologic malignancies harboring PIK3CA mutations. J Clin
Oncol. 30:777–782. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bian X, Gao J, Luo F, Rui C, Zheng T, Wang
D, Wang Y, Roberts TM, Liu P, Zhao JJ, et al: PTEN deficiency
sensitizes endometrioid endometrial cancer to compound PARP-PI3K
inhibition but not PARP inhibition as monotherapy. Oncogene.
37:341–351. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Philip CA, Laskov I, Beauchamp MC, Marques
M, Amin O, Bitharas J, Kessous R, Kogan L, Baloch T, Gotlieb WH, et
al: Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial
cancer cell lines to PARP inhibitors. BMC Cancer. 17:6382017.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hasegawa K, Kagabu M, Mizuno M, Oda K,
Aoki D, Mabuchi S, Kamiura S, Yamaguchi S, Aoki Y, Saito T, et al:
Phase II basket trial of perifosine monotherapy for recurrent
gynecologic cancer with or without PIK3CA mutations. Invest
New Drugs. 35:800–812. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mirantes C, Dosil MA, Eritja N, Felip I,
Gatius S, Santacana M, Matias-Guiu X and Dolcet X: Effects of the
multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient
neoplasias. Eur J Cancer. 63:74–87. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
McCormick A, Earp E, Leeson C, Dixon M,
O'Donnell R, Kaufmann A and Edmondson RJ: Phosphatase and Tensin
Homolog is a potential target for ovarian cancer sensitization to
cytotoxic agents. Int J Gynecol Cancer. 26:632–639. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tsiatis AC, Norris-Kirby A, Rich RG, Hafez
MJ, Gocke CD, Eshleman JR and Murphy KM: Comparison of Sanger
sequencing, pyrosequencing, and melting curve analysis for the
detection of KRAS mutations: Diagnostic and clinical
implications. J Mol Diagn. 12:425–432. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ihle MA, Fassunke J, König K, Grünewald I,
Schlaak M, Kreuzberg N, Tietze L, Schildhaus HU, Büttner R and
Merkelbach-Bruse S: Comparison of high resolution melting analysis,
pyrosequencing, next generation sequencing and immunohistochemistry
to conventional Sanger sequencing for the detection of p.V600E and
non-p V600E BRAF mutations. BMC Cancer. 14:132014.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Li BS, Wang XY, Ma FL, Jiang B, Song XX
and Xu AG: Is high resolution melting analysis (HRMA) accurate for
detection of human disease-associated mutations? A meta analysis.
PLoS One. 6:e280782011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Vossen RH, Aten E, Roos A and den Dunnen
JT: High-resolution melting analysis (HRMA): More than just
sequence variant screening. Hum Mutat. 30:860–866. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Colombo N, Creutzberg C, Amant F, Bosse T,
González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza
MR, et al: ESMO-ESGO-ESTRO consensus conference on endometrial
cancer diagnosis, treatment and follow-up. Int J Gynecol Cancer.
26:2–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kafshooz L, Kafshdooz T, Tabrizi AD,
Mohaddes Ardabili SM, Ardabili M, Arkbazadeh A, Gharesouran J,
Ghojazadeh M and Farajnia S: Role of exon 7 PTEN gene in
endometrial carcinoma. Asian Pac J cancer Prev. 16:4521–4524. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Simi L, Pratesi N, Vignoli M, Sestini R,
Cianchi F, Valanzano R, Nobili S, Mini E, Pazzagli M and Orlando C:
High-resolution melting analysis for rapid detection of KRAS,
BRAF, and PIK3CA gene mutations in colorectal cancer. Am
J Clin Pathol. 130:247–253. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ousati Ashtiani Z, Mehrsai AR, Pourmand MR
and Pourmand GR: High resolution melting analysis for rapid
detection of PIK3CA gene mutations in bladder cancer: A mutated
target for cancer therapy. Urol J. 15:26–31. 2018.PubMed/NCBI
|
|
56
|
Martínez-Carretero C, Pascual FI, Rus A
and Bernardo I: Detection of EGFR mutations in patients with
non-small cell lung cancer by high resolution melting. Comparison
with other methods. Clin Chem Lab Med. 55:1970–1978. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Tsiatis AC, Norris-Kirby A, Rich G, Hafez
MJ, Gocke CG, Eshleman JR and Murphy KM: Comparison of Sanger
sequencing, pyrosequencing, and melting curve analysis for the
detection of KRAS mutations: Diagnostic and clinical
implications. J Mol Diagn. 12:425–432. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Engelman A: Targeting PI3K signaling in
cancer: Opportunities, challenges and limitations. Nat Rev Cancer.
8:550–562. 2009. View Article : Google Scholar
|
|
59
|
Di Nicolantonio F, Arena S, Tabernero J,
Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin
D, Mazzucchelli L, et al: Deregulation of the PI3K and KRAS
signaling pathways in human cancer cells determines their response
to everolimus. J Clin Invest. 120:2558–2866. 2010. View Article : Google Scholar
|
|
60
|
Ni X, Zhang W and Huang RS:
Pharmacogenomics discovery and implementation in genome-wide
association studies era. Wiley Interdiscip Rev Syst Biol Med.
5:1–9. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Tsimberidou AM, Iskander NG, Hong DS,
Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra
R, et al: Personalized medicine in a phase I clinical trials
program: The MD Anderson Cancer Center initiative. Clin Cancer Res.
15:6373–6383. 2012. View Article : Google Scholar
|
|
62
|
Westin SN, Ju Z, Broaddus RR, Krakstad C,
Li J, Pal N, Lu KH, Coleman RL, Hennessy BT, Klempner SJ, et al:
PTEN loss is a context-dependent outcome determinant in obese and
non-obese endometrioid endometrial cancer patients. Mol Oncol.
9:1694–1703. 2015. View Article : Google Scholar : PubMed/NCBI
|
